Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: BBT-401-1S or Placebo
- Registration Number
- NCT04596293
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Brief Summary
This is a randomised, double-blind, placebo-controlled, proof of clinical principle study to explore the efficacy and safety of orally administered BBT-401-1S in subjects with ulcerative colitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
- Male or female, of any race, ≥18 and ≤60 years of age.
- Have been diagnosed with active UC for ≥3 months prior to Day 1, as determined by clinical and endoscopic evidence and documented in a histopathology evaluation.
- Have a total Mayo score ≥6, an endoscopic subscore ≥2, rectal bleeding subscore ≥1, and a stool frequency subscore ≥1, regardless of standard of care history.
- Able to comprehend and willing to voluntarily sign an ICF and to abide by the study restrictions.
-
Have received:
- intravenous corticosteroids, rectally administered corticosteroids, or rectally administered 5-aminosalicylic acid within 3 weeks, or
- Janus kinase (JAK) inhibitors within 2 weeks, or
- cyclosporine, mycophenolate, tacrolimus, or methotrexate within 5 weeks, or
- anti-TNF-α biologics within 9 weeks, or
- any other biologics (including ustekinumab and vedolizumab) for the treatment of UC within 12 weeks.
-
Have received orally administered azathioprine or 6-mercaptopurine that has been stable for <8 weeks.
-
Have received orally administered 5-aminosalicylic acid, sulphasalazine, or low-dose corticosteroids (prednisolone ≤20 mg/day or equivalent) that have been stable for <5 weeks.
-
Have received any other concomitant medications for UC that have been stable (ie, have not started dosing with a new drug or had a change to their dosing regimen) for <7 days or 5 half-lives, whichever is longer.
-
Have Crohn's disease, indeterminate colitis, ischaemic colitis, fulminant colitis, toxic megacolon, chronic (as determined by the investigator) pancolitis, confined proctitis (distal, ≤15 cm), or symptomatic intestinal stenosis.
-
Have a history of extensive colonic resection (subtotal or total colectomy) or are anticipated to require surgical intervention for UC.
-
Have an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
-
Have a positive test for Clostridium difficile, or have evidence of treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to Day 1.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BBT-401-1S (1,600mg) BBT-401-1S or Placebo * Induction Phase: BBT-401 1600mg for 8 weeks * Extension Phase: After 8 weeks, Participants will continue the same treatment for 8 weeks Placebo BBT-401-1S or Placebo * Induction Phase: Placebo for 8 weeks * Extension Phase: After 8 weeks, * Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks * Participants who did not achieve clinical remission in the induction phase will receive BBT-401 800mg for 8 weeks BBT-401-1S (800mg) BBT-401-1S or Placebo * Induction Phase: BBT-401 800mg for 8 weeks * Extension Phase: After 8 weeks, * Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks * Participants who did not achieve clinical remission in the induction phase will receive BBT-401 1600mg for 8 weeks
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score at Day 57 Day 57 Clinical Response was defined as a Total Mayo Score, as measured by a reduction of ≥ 3 points and ≥ 30% improvement from baseline of Total Mayo Score, which included a decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore ≤ 1
- Secondary Outcome Measures
Name Time Method Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score at Day 57 Day 57 Clinical Remission was defined as a Total Mayo score, as measured by a total Mayo score of ≤ 2 points, with no individual subscore exceeding 1 point. Change from baseline to Day 57 in Total Mayo Score. The Total Mayo Score is consisted of 4 subscores (stool frequency, rectal bleeding, findings on endoscopy, physician's global assessment), each graded from 0 to 3 with higher scores indicating more severe disease
Percentage of Participants Who Achieved an Endoscopic Remission at Day 57 Day 57 Endoscopic Remission was defined as a Mayo endoscopic subscore of 0 or 1. Change from baseline to Day 57 in Total Mayo Score. The Total Mayo Score is consisted of 4 subscores (stool frequency, rectal bleeding, findings on endoscopy, physician's global assessment), each graded from 0 to 3 with higher scores indicating more severe disease
Change From Baseline to Day 57 in Total Mayo Score Baseline, Day 57 Change from Baseline to Day 57 in Total Mayo Score. Change from baseline to Day 57 in Total Mayo Score. The Total Mayo Score, ranged from 0 to 12, are sum of 4 subscores. Subscores are stool frequency, rectal bleeding, findings on endoscopy, and physician's global assessment, each graded from 0 to 3 with higher scores indicating more severe disease.
Trial Locations
- Locations (29)
Premier Gastroenterology
🇺🇸Little Rock, Arkansas, United States
Saini Surinder S MD
🇺🇸Fountain Valley, California, United States
Gastro Care Institute
🇺🇸Lancaster, California, United States
Discovery Clinical Trials - AACT
🇺🇸Pflugerville, Texas, United States
Intercity Gastroentertology
🇺🇸Fresh Meadows, New York, United States
Velocity Clinical Research
🇺🇸Riverton, Utah, United States
Inje University Haeundae Paik Hospital
🇰🇷Haeundae, Busan Gwang'yeogsi, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Bugok, Daegu, Korea, Republic of
Yeungnam University Hospital
🇰🇷Daegu, Gwang'yeogsi, Korea, Republic of
Inje University, Seoul Paik Hospital
🇰🇷Junggu, Seoul, Korea, Republic of
Uniwersytecki Szpital Kliniczny Nr. 1 im. Norberta Barlickiego
🇵🇱Łódź, Łódzkie, Poland
VITA LONGA Sp. z o.o.
🇵🇱Katowice, Śląskie, Poland
Municipal Non-Profit Enterprise Kherson City Clinical Hospital named after E.E.Karabelesha of Kherso
🇺🇦Kherson, Khersons'ka Oblast, Ukraine
Medical Centre of the Limited Liability Company Medical Clinic Blagomed, Treatment and Diagnostic Di
🇺🇦Kyiv, Kyïv, Ukraine
Medical Center RCLIN Ukraine of the Limited Liability Company Cardiocom
🇺🇦Obukhiv, Kyïv, Ukraine
Communal Non-profit enterprise Vinnytsya city clinical hospital 1 gastroenterology department
🇺🇦Vinnytsya, Vinnyts'ka Oblast, Ukraine
Medical Center of LLC Oxford Medical-Vinnytsia
🇺🇦Vinnytsia, Vinnyts'ka Oblast, Ukraine
Municipal Non-Profit Enterprise of the Kyiv Regional Council Kyiv Regional Hospital, Therapeutics De
🇺🇦Kyiv, Ukraine
Javara Research
🇺🇸Charlotte, North Carolina, United States
West Jordan
🇺🇸West Jordan, Utah, United States
Inves Clinic
🇺🇸McAllen, Texas, United States
Korea University Ansan Hospital
🇰🇷Ansan, Gyeonggido, Korea, Republic of
The Catholic university of Korea, Seoul St Mary's Hospital
🇰🇷Seocho, Seoul Teugbyeolsi, Korea, Republic of
Centrum Medyczne Pratia Bydgoszcz
🇵🇱Bydgoszcz, Kujawsko-pomorskie,, Poland
Centrum Medyczne Melita Medical
🇵🇱Wrocław, Wroclaw, Poland
Municipal Non-Profit Enterprise City Clinical Hospital No. 2 named after prof. O.O. Shalimov of the
🇺🇦Kharkiv, Kharkivs'ka Oblast, Ukraine
Communal Non-profit enterprise Kyiv City Clinical Hospital No. 18, of the executive body of the Kyiv
🇺🇦Kyiv, Kyïv, Ukraine
Wonju Severance Christian Hospital
🇰🇷Wŏnju, Gang'weondo, Korea, Republic of
Municipal Enterprise Volyn Regional Clinical Hospital of the Volyn Regional Council, Department of S
🇺🇦Luts'k, Vinnyts'ka Oblast, Ukraine